NantBioscience Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10


  • Latest Deal Type
  • 2ndary - Private

NantBioscience General Information


Developer of molecularly targeted drugs designed to treat cancer, infectious diseases, and inflammatory diseases. The company's drugs are targeted at tumor signaling pathways in patients with specific genetic mutations, enabling patients to have access to new therapeutic alternatives.

Contact Information

Formerly Known As
NantBio, Nant Discovery & Developement
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 9920 Jefferson Boulevard
  • Culver City, CA 90232
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NantBioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Apr-2023 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jun-2015 00000 00000 00000 Completed Generating Revenue
To view NantBioscience’s complete valuation and funding history, request access »

NantBioscience Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.0 000 000 00 000 00.000
To view NantBioscience’s complete cap table history, request access »

NantBioscience Patents

NantBioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220275098-A1 Anti-cd30 monoclonal antibodies and chimeric antigen receptors Active 01-Mar-2021 00000000000
CA-3211463-A1 Anti-cd30 monoclonal antibodies and chimeric antigen receptors Pending 01-Mar-2021 00000000000
AU-2022231068-A1 Anti-cd30 monoclonal antibodies and chimeric antigen receptors Pending 01-Mar-2021 00000000000
US-20240124598-A1 Anti-cd30 monoclonal antibodies and chimeric antigen receptors Pending 01-Mar-2021 00000000000
EP-4301783-A1 Anti-cd30 monoclonal antibodies and chimeric antigen receptors Pending 01-Mar-2021 C07K16/2878
To view NantBioscience’s complete patent history, request access »

NantBioscience Executive Team (3)

Name Title Board Seat Contact Info
A Banaag Chief Financial Officer
Patrick Soon-Shiong MD Founder, Chief Executive Officer, Board Member & Managing Director
You’re viewing 2 of 3 executive team members. Get the full list »

NantBioscience Board Members (1)

Name Representing Role Since
Mark Burnett NantBioscience Board Member 000 0000
To view NantBioscience’s complete board members history, request access »

NantBioscience Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NantBioscience Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alethia Biotherapeutics 01-Nov-2023 0000000000 Drug Discovery
To view NantBioscience’s complete acquisitions history, request access »

NantBioscience Subsidiaries (1)

Company Name Industry Location Founded
Alethia Biotherapeutics Drug Discovery Montreal, Canada 0000
To view NantBioscience’s complete subsidiaries history, request access »

NantBioscience FAQs

  • When was NantBioscience founded?

    NantBioscience was founded in 2013.

  • Who is the founder of NantBioscience?

    Patrick Soon-Shiong MD is the founder of NantBioscience.

  • Who is the CEO of NantBioscience?

    Patrick Soon-Shiong MD is the CEO of NantBioscience.

  • Where is NantBioscience headquartered?

    NantBioscience is headquartered in Culver City, CA.

  • What is the size of NantBioscience?

    NantBioscience has 10 total employees.

  • What industry is NantBioscience in?

    NantBioscience’s primary industry is Drug Discovery.

  • Is NantBioscience a private or public company?

    NantBioscience is a Private company.

  • What is NantBioscience’s current revenue?

    The current revenue for NantBioscience is 000000.

  • How much funding has NantBioscience raised over time?

    NantBioscience has raised $205M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »